MARKET

PRPH

PRPH

Prophase Labs Inc
NASDAQ
6.47
+0.21
+3.35%
Closed 16:00 03/28 EDT
OPEN
6.46
PREV CLOSE
6.26
HIGH
6.55
LOW
6.23
VOLUME
16.00K
TURNOVER
0
52 WEEK HIGH
9.94
52 WEEK LOW
4.050
MARKET CAP
116.75M
P/E (TTM)
-6.6339
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PRPH last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at PRPH last week (0311-0315)?
Weekly Report · 03/18 09:51
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023
ProPhase Labs reported earnings per share of -51 cents. The company reported revenue of $4.35 million. This was 59.30% below the analyst estimate for the company to report revenue of  $10.69 million. The company also reported lower than expected earnings.
Investorplace · 03/15 16:53
ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate
ProPhase Labs reports quarterly losses of $0.51 per share. The company reported quarterly sales of $4.35 million. ProPhase Labs missed the analyst consensus estimate of $10.69 million by 59.30%. The company also missed the quarterly sales estimate by 80.06%.
Benzinga · 03/15 12:10
*ProPhase Labs 2023 Loss/Shr $0.98 >PRPH
Dow Jones · 03/15 12:02
ProPhase Labs GAAP EPS of -$0.98 misses by $0.24, revenue of $45.2M misses by $6.38M
Seeking Alpha · 03/15 12:01
*ProPhase Labs 2023 Rev $45.2M >PRPH
Dow Jones · 03/15 12:01
BRIEF-ProPhase Labs FY Adjusted EBITDA USD -10.558 Million
Reuters · 03/15 12:00
More
About PRPH
ProPhase Labs, Inc. is a diagnostics, genomics and biotech company. The Company leverages its Clinical Laboratory Improvement Amendments (CLIA) lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. It provides traditional CLIA molecular laboratory services, including coronavirus disease (COVID-19) testing. It also operates Pharmaloz, a contract manufacturing subsidiary, which offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores. The Company's wholly owned subsidiary ProPhase Diagnostics, Inc, offers a broad array of clinical diagnostic and testing services at its CLIA-certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. It also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.

Webull offers ProPhase Labs Inc stock information, including NASDAQ: PRPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRPH stock methods without spending real money on the virtual paper trading platform.